We have located links that may give you full text access.
JOURNAL ARTICLE
META-ANALYSIS
REVIEW
Tc-99m sestamibi scintimammography for the diagnosis of breast cancer: meta-analysis and meta-regression.
Nuclear Medicine Communications 2011 November
Tc-99m sestamibi (MIBI) is a relatively noninvasive diagnostic modality in the evaluation of breast cancer. The purpose of this study was to review the existing literature on the accuracy of Tc-99m MIBI in the diagnosis of breast cancer. After a systematic review of English-language studies, the sensitivity, specificity, and other measures of accuracy of Tc-99m MIBI in the diagnosis of breast cancer were pooled using random-effects models. Summary receiver operating characteristic curves were used to summarize the overall test performance. Forty-five studies met our inclusion criteria. The summary estimates for Tc-99m MIBI in the diagnosis of breast cancer in the studies included were as follows: sensitivity, 0.83 [95% confidence interval (CI), 0.82-0.84]; specificity, 0.85 (95% CI, 0.83-0.86); positive likelihood ratio, 5.06 (95% CI, 4.26-6.01); negative likelihood ratio, 0.20 (95% CI, 0.17-0.24); and diagnostic odds ratio, 27.63 (95% CI, 21.63-36.10). For patients with a palpable mass, the sensitivity and specificity were 87 and 86%, respectively. For patients without a palpable mass, the sensitivity and specificity were 59 and 89%, respectively. Tc-99m MIBI has a high level of overall accuracy for the diagnosis of breast cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app